One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset
Open Access
- 11 September 2023
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 18 (9) , e0290893
Abstract
Background: There is increasing data that show a persistently impaired pulmonary function upon recovery after severe infection. Little is known however about the extent, recovery and determinants of pulmonary impairment across the full spectrum of COVID-19 severity over time. Methods: In a well characterized, prospective cohort of both hospitalised and non-hospitalised individuals with SARS-CoV-2 infection, the RECoVERED study, pulmonary function (diffusing capacity for carbon monoxide (DLCO)) and spirometry) was measured until one year after disease onset. Additionally, data on sociodemographics, clinical characteristics, symptoms, and health-related quality of life (HRQL) were collected. Pulmonary function and these determinants were modelled over time using mixed-effect linear regression. Determinants of pulmonary function impairment at 12 months after disease onset were identified using logistic regression. Findings: Between May 2020 and December 2021, 301 of 349 participants underwent at least one pulmonary function test. After one year of follow-up, 25% of the participants had an impaired pulmonary function which translates in 11%, 22%, and 48% of the participants with mild, moderate and severe/critical COVID-19. Improvement in DLCO among the participants continued over the period across one, six and twelve months. Being older, having more than three comorbidities (p<0·001) and initial severe/critical disease (p<0·001) were associated with slower improvement of pulmonary function over time, adjusted for age and sex. HRQL improved over time and at 12 months was comparable to individuals without impaired pulmonary function. Interpretation: The prevalence of impaired pulmonary function after twelve months of follow-up, was still significant among those with initially moderate or severe/critical COVID-19. Pulmonary function increased over time in most of the severity groups. These data imply that guidelines regarding revalidation after COVID-19 should target individuals with moderate and severe/critical disease severities.Keywords
Funding Information
- ZonMw (10150062010002)
- Public Health Service of Amsterdam (R&D)
This publication has 27 references indexed in Scilit:
- Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recoveryeClinicalMedicine, 2020
- Operational considerations for case management of COVID-19 in health facility and community. Interim guidancePediatria i Medycyna Rodzinna, 2020
- Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysisJournal of Rehabilitation Medicine, 2020
- A logistic regression analysis of risk factors in ME/CFS pathogenesisBMC Neurology, 2019
- Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical StatementAmerican Journal of Respiratory and Critical Care Medicine, 2019
- Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for CaucasiansEuropean Respiratory Journal, 2017
- Physical Complications in Acute Lung Injury SurvivorsCritical Care Medicine, 2014
- Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equationsEuropean Respiratory Journal, 2012
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.1992
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992